Clyra Bio
Clyra Bio is building cross-species AI foundation models that align naturally occurring canine cancers with human molecular and clinical data to model conserved tumor states and improve oncology drug-development decisions.
Starting with survival-linked patient stratification in sarcoma.
Canine cancer is our data advantage.
Human oncology is our market.
Cross-species AI foundation model
Shared biological representations across species
The data bottleneck
Drug development depends on understanding how tumors evolve, respond, and recur. But human oncology datasets are often slow to assemble, fragmented across institutions, and weakly connected to longitudinal treatment and outcome data. The result is limited biological signal at the moments when drug developers must make critical decisions about patient selection, biomarkers, trial design, and therapeutic strategy.
Naturally Occurring Disease
Cancers arise spontaneously rather than through artificial experimental induction.
Longitudinal Clinical Trajectories
Treatment, progression, recurrence, and survival can be linked to molecular profiles.
Human-Relevant Biology
Shared tumor biology creates opportunities to identify conserved disease states across species.
The Clyra Platform
Clyra is developing cross-species AI foundation models that learn shared representations from canine and human molecular, clinical, treatment, and outcome data. The platform is designed to distinguish species-specific noise from conserved cancer biology, revealing tumor states that carry translational value across species.
01 · Multimodal Cancer Data
Genomic, transcriptomic, immune, treatment, clinical, and longitudinal outcome signals.
02 · Cross-Species Alignment
AI models align comparable biological patterns across canine and human cancers.
03 · Conserved Tumor States
The platform identifies molecular and microenvironment states shared across species.
04 · Outcome-Linked Subgroups
Tumor states are connected to progression, recurrence, survival, response, and resistance.
05 · Development Intelligence
Outputs support patient stratification, trial design, biomarker strategy, and therapeutic decisions.
First Product
Patient Subgroup Map
Identify biologically distinct patient populations using integrated molecular profiles.
Survival-Linked Stratification
Connect tumor states with progression, recurrence, and survival trajectories.
Biomarker Strategy
Prioritize molecular and microenvironment hypotheses for retrospective or prospective validation.
Clinical-Development Decisions
Support trial enrichment, subgroup analysis, response interpretation, and program strategy.
Sharper biological hypotheses before larger clinical commitments.
Starting Point
Strong Translational Bridge
Naturally occurring canine sarcomas provide complementary evidence relevant to human disease.
High Unmet Stratification Need
Rare and heterogeneous patient populations make clinical signal difficult to interpret.
Platform Expansion Potential
The same cross-species architecture can extend into additional cancer types and development questions.
Platform Roadmap
Now
Patient Stratification
Identify survival-linked and biologically distinct patient subgroups.
Next
Response and Resistance Modeling
Characterize tumor states associated with treatment benefit, non-response, recurrence, and resistance.
Expansion
Target and Therapeutic Discovery
Use conserved cross-species biology to prioritize pathways, targets, combinations, and development hypotheses.
The first product creates the workflow. Each program expands the data and model advantage.
01
Integrated Molecular Subgroup Map
Patient subgroups defined by molecular, immune, clinical, and outcome-linked signals.
02
Outcome-Linked Stratification Hypothesis
Subgroup hypotheses associated with progression, recurrence, survival, response, or resistance.
03
Treatment-Biology Interpretation
Asset-specific interpretation of target biology, mechanism of action, tumor microenvironment, and resistance.
04
Trial and Biomarker Strategy
Recommendations for enrichment, subgroup analysis, biomarker development, and clinical interpretation.
05
Validation Roadmap
A plan for retrospective human analysis, independent validation, or prospective study design.